Project Grant R01HL177014
Award Date 8/1/25
Completion Date 5/31/29
Dollars Obligated $889K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award of $636,982.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to comprehensively investigate the proteolytic mechanisms that govern factor VIII regulation before and after activation, which is critical for maintaining normal blood clotting and preventing bleeding disorders like hemophilia A. The project aims to understand how proteolysis of factor...
- This Project Grant award for $314,363, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel gene therapy technology called STITCHR to enable full gene replacement for Hemophilia A. The proposed research will engineer robust adeno-associated virus (AAV) constructs to deliver and express the full-length Factor VIII gene, addressing the limitations of current truncated versions. The project will...
- This Project Grant award of $234,750.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to examine the immunological mechanisms that initiate and orchestrate the development of anti-factor VIII alloantibodies, known as inhibitors, in patients with severe hemophilia A. The research is being conducted by Emory University and seeks to identify key immune pathways and risk factors that predict the likelihood of inhibitor development, with the goal...
- This Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) provides $814,209 to the Fred Hutchinson Cancer Center to support research on the use of targeted nanoparticles for in vivo hematopoietic stem cell gene therapy. The project aims to refine the target for hematopoietic stem cell gene therapy and develop a method to genetically modify these cells directly in the patient, which would improve the feasibility...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $704,635 to the University of Florida to develop optimized adeno-associated virus (AAV) vectors for gene therapy of hemophilia. Specifically, the award aims to engineer both capsid- and genome-modified AAV3 vectors that can transduce human hepatocytes more efficiently than current AAV5 vectors, potentially reducing the required vector dose and...
- This Project Grant award of $395,314 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University aims to define the key cellular components and early immunologic events that mediate factor VIII immunity in persons with hemophilia A. The research will investigate the role of type 2 conventional dendritic cells (CDC2) in the development of anti-factor VIII antibodies, with the long-term goal of developing targeted...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate a novel biotherapeutic immunocytokine (F5111-IC) for suppressing inhibitor formation in hemophilia patients. The total award amount is $1,165,276, with a project period from January 1, 2025 to November 30, 2026. The primary services under this award involve preclinical assessments of the F5111-IC treatment platform to validate...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $765,622 to Yale University, with a sub-award to the Children's Hospital of Philadelphia, to develop orally bioavailable protein degraders targeting fetal hemoglobin gene repressors. The goal is to elevate fetal hemoglobin levels and prevent erythroid sickling to treat sickle cell disease. The award period runs from January 1, 2025 to November 30, 2028....
- This Project Grant award for $445,000.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The funding supports research conducted by The Children's Hospital of Philadelphia (CHOP) to study the role of neutrophil extracellular traps (NETs) in inflammatory and thrombotic diseases. The project aims to characterize the role of NETs in immune homeostasis, determine the mechanisms by which NET stabilization...
- This federal Project Grant award of $441,375.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and optimize a dual adeno-associated virus (AAV) system with intein technology to deliver full-length, functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to airway epithelial cells of cystic fibrosis (CF) patients. The goal is to restore CFTR function in CF patients, particularly those...